[ad_1]
– The ORR observed in patients with the following diseases is 72% >2L HER2-positive gastric cancer or gastroesophageal junction cancer
– The estimated OS at 12 months is 76%
– ALX Oncology will host a conference call on July 6day 8:30 a.m. EDT
Burlingame, California, July 3, 2021 (Global News Service) – ALX Oncology Holdings Inc., (“ALX Oncology”) (NASDAQ:Ailes), a clinical-stage immuno-oncology company that develops therapies to block the CD47 checkpoint mechanism, today announced the release of the latest clinical data of its ongoing ASPEN-01 trial, which evaluates ALX148 combined with trastuzumab and chemotherapy in the treatment of stomach or stomach Esophageal junction cancer (“GC”).New results were shared in the oral report of the 23rd sessionroad The World Gastrointestinal Cancer Congress has shown that ALX148 combined with trastuzumab and chemotherapy is highly active and well tolerated in second-line or above patients (“>2L”) HER2 positive GC [abstract SO-31].
Hyun Cheol Chung said: “The ongoing data from this clinical trial is very encouraging, indicating that the combination of ALX148 with trastuzumab, ramucirumab, and paclitaxel may be effective during or after previous trastuzumab and chemotherapy. Patients with disease progression provide important progress.”, Ph.D., researcher at ASPEN-01, Yonsei Cancer Center, Korea. “Importantly, these results also support the tolerability of ALX148, further distinguishing it as a unique CD47 blocker that can be used in combination with a series of anticancer drugs including chemotherapy.”
As of the data cutoff date of May 3, 2021, 18 patients have received 10 mg/kg…
The full story on Benzinga.com
[ad_2]
Source link
